Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent (MEND II)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Amaranth Medical Inc.
Sponsor:
Information provided by (Responsible Party):
Amaranth Medical Inc.
ClinicalTrials.gov Identifier:
NCT02189499
First received: July 9, 2014
Last updated: October 16, 2014
Last verified: October 2014
  Purpose

The purpose of this study is to evaluate the safety and feasibility of a new coronary artery stent for treating blockages in the arteries supplying blood to the heart muscle. The Amaranth FORTITUDE scaffold releases a drug (sirolimus) to reduce the likelihood of the treated blood vessel developing a new blockage. In addition, the scaffold dissolves away over time, leaving no permanent implant after the blood vessel has healed. This study will will be the first evaluation of this stent in humans.


Condition Intervention Phase
Coronary Artery Disease
Myocardial Ischemia
Device: AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Amaranth Endovascular Study of a Drug-Eluting Bioresorbable Coronary Scaffold

Further study details as provided by Amaranth Medical Inc.:

Primary Outcome Measures:
  • Incidence of target vessel failure [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]
    Defined as the composite rate of cardiac death (using the Academic Research Consortium [ARC] definition), target vessel myocardial infarction (using the Third Universal Definition of MI), or clinically indicated target lesion revascularization (using the ARC definition).

  • In-scaffold late lumen loss [ Time Frame: 9 months ] [ Designated as safety issue: No ]
    Defined as the amount of vessel lumen diameter (in mm) lost/gained at the time of follow-up compared to the immediate post-treatment result, as measured by quantitative coronary angiography (QCA). The assessment is made within the segment of vessel including the scaffold.


Secondary Outcome Measures:
  • Clinical device success [ Time Frame: intraoperative ] [ Designated as safety issue: No ]
    Defined as successful delivery and deployment of the investigational scaffold at the intended target lesion with attainment of a final residual stenosis of < 50% of the target lesion by quantitative coronary angiography (QCA) after the index procedure.

  • Clinical procedure success [ Time Frame: Participants will be followed for the duration of their hospital stay, an expected average of 1-2 days ] [ Designated as safety issue: No ]
    Defined as successful delivery and deployment of the investigational scaffold at the intended target lesion, with attainment of a final residual stenosis of < 50% of the target lesion by quantitative coronary angiography (QCA) using any adjunctive device, without the occurrence of major adverse clinical events (cardiac death, target vessel myocardial infarction, or clinically indicated target lesion revascularization) during the duration of the subject's hospital stay (an average of 1-2 days).


Other Outcome Measures:
  • In-segment/in-scaffold late lumen loss [ Time Frame: 9 months and 2 years ] [ Designated as safety issue: No ]
    Defined as the amount of vessel lumen diameter (in mm) lost/gained at the time of follow-up compared to the immediate post-treatment result, as measured by quantitative coronary angiography; the assessment is made both within the scaffold itself ("in-scaffold") and within the segment of vessel including the scaffold and 5 mm proximal and distal to the scaffold ("in-segment").

  • In-scaffold percent volume obstruction [ Time Frame: 9 months and 2 years ] [ Designated as safety issue: No ]
    Defined as the difference between the volume enclosed within the scaffold and the corresponding vessel lumen, expressed as a percentage of the scaffold volume at the time of follow-up, measured using optical coherence tomography (OCT)

  • Stent thrombosis [ Time Frame: Hospital discharge, 30 days, 9 months, and 2 years ] [ Designated as safety issue: Yes ]
    Defined using the ARC "definite" or "probable" stent thrombosis definitions.

  • In-scaffold/in-segment binary restenosis rate [ Time Frame: 9 months and 2 years ] [ Designated as safety issue: No ]
    Defined as the percentage of treated coronary lesions with a residual diameter stenosis over 50% at the time of follow-up, as measured by quantitative coronary angiography (QCA). The assessments are made both within the scaffold itself ("in-scaffold") and within the segment of vessel including the scaffold and 5 mm proximal and distal to the scaffold ("in-segment").

  • Incomplete scaffold strut apposition to the vessel wall [ Time Frame: 9 months and 2 years ] [ Designated as safety issue: No ]
    Defined as the number (or percentage) of scaffold struts not in direct contact with the vessel wall, either persisting from the implantation of the scaffold or newly occurring after the time of scaffold implantation, assessed at follow-up using OCT.


Estimated Enrollment: 50
Study Start Date: September 2014
Estimated Study Completion Date: January 2020
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Coronary Scaffold Implantation
AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
Device: AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
Other Name: Coronary stent

Detailed Description:

The objective of this first-in-man study is to evaluate the safety and feasibility of the AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold for use in the treatment of single, de novo, stenotic native coronary artery lesions in patients undergoing elective percutaneous coronary intervention. The scaffold is a single-use device comprised of a balloon-expandable, intracoronary drug coated scaffold pre-mounted on a rapid-exchange delivery catheter. The scaffold is made of Poly-L-Lactide (PLLA) and is coated with a polymer-antiproliferative drug (sirolimus) matrix. The scaffold provides mechanical support similar to a metallic stent to the vessel while it is healing, and then gradually breaks down over time leaving no permanent implant in the treated vessel.

The study design is a prospective, non-randomized, feasibility trial. It will enroll a maximum of 50 patients from multiple investigational centers in Columbia. Eligible patients who are at least 18 years of age diagnosed with symptomatic ischemic disease due to a discrete, single, de novo, stenotic lesion in native coronary artery will be asked to participate in this study. After treatment with the investigational device, subjects will be followed for five years. Safety of the device will be evaluated using the incidence of target vessel failure during the follow-up period. Efficacy will be assessed using the in-scaffold late lumen loss measured by quantitative coronary angiography at nine months.

  Eligibility

Ages Eligible for Study:   18 Years to 84 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

General

  1. Subject is ≥ 18 years of age and < 85 years of age.
  2. Subject agrees not to participate in any other investigational device or drug study for a period of two years following the index procedure. Questionnaire-based studies, or other studies that are non-invasive and do not require investigational devices or medications are allowed.
  3. Subject (or their legally authorized representative) provides written informed consent prior to any study-related procedure, using the form approved by the local Ethics Committee.
  4. Subject has:

    1. evidence of myocardial ischemia (e.g., stable angina [Canadian Cardiovascular Society 1, 2, 3, or 4] or unstable angina [Braunwald Class 1-3, B-C], or silent ischemia with supporting imaging studies [ETT, SPECT, stress echocardiography, or Cardiac CT]), or
    2. low or intermediate risk NSTEMI, or
    3. evidence of myocardial ischemia in a coronary territory previously affected by STEMI as long as the lesion fulfills the angiographic inclusion criteria and the intervention performed ≥ 6 months following the clinical event.
  5. Subject is an acceptable candidate for coronary artery bypass graft (CABG) surgery.
  6. Patient agrees to complete all protocol required follow-up visits, including angiograms and OCT exams.
  7. Percutaneous interventions for lesions in a non-target vessel are allowed if done ≥ 30 days prior to or planned to be done ≥ 9 months after the index procedure.
  8. Percutaneous interventions for lesions in the target vessel are allowed if done ≥ 6 months prior to or planned to be done ≥ 9 months after the index procedure.

Angiographic

  1. Patient indicated for elective stenting of a single, de novo, stenotic lesion in a native coronary artery.
  2. Target lesion must measure ≤ 14 mm in length by on-line QCA.
  3. Lesion must be located in a native coronary artery with a diameter (average of distal and proximal to lesion by IVUS) of 2.5 mm to 3.7 mm.
  4. Target lesion must be in a major artery or branch with a visually estimated diameter stenosis of ≥ 50% and < 100% with a Thrombolysis in Myocardial Infarction (TIMI) flow of ≥ 1.

Exclusion Criteria:

General

  1. Patient has known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, antiplatelet medication specified for use in the study (clopidogrel, prasugrel, and ticagrelor), poly (L-lactide), platinum-iridium, or contrast sensitivity that cannot be adequately pre-medicated.
  2. Patient has evolving ST segment elevation myocardial infarction (STEMI).
  3. Patient has current unstable arrhythmias.
  4. Patient has a left ventricular ejection fraction (LVEF) < 30%.
  5. Patient has received a heart transplant or any other organ transplant, or is on a waiting list for any organ transplant.
  6. Patient has any previous stent placements ≤ 15 mm (proximal or distal) of the target lesion.
  7. Patient is receiving or scheduled to receive chemotherapy for malignancy ≤ 30 days prior to or after the index procedure.
  8. Patient is receiving immunosuppressant therapy and/or has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus, rheumatoid arthritis, severe asthma requiring immunosuppressive medication, etc.).
  9. Patient is receiving or scheduled to receive chronic anticoagulation therapy (e.g., heparin, Coumadin) that cannot be stopped and restarted according to local hospital standard procedures.
  10. Elective surgery is planned ≤ 9 months after the index procedure that will require discontinuation of anti-platelet medications.
  11. Patient has a platelet count < 100,000 cells/mm^3 or > 700,000 cells/mm^3, a WBC of < 3,000 cells/mm^3, or documented or suspected liver disease (including laboratory evidence of hepatitis).
  12. Patient has known renal insufficiency (e.g., eGFR < 60 ml/kg/m^2 or serum creatinine level of > 2.5 mg/dL, or subject on dialysis).
  13. Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
  14. Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) ≤ 6 months prior to the index procedure.
  15. Patient has had a significant GI or urinary bleed ≤ 6 months prior to the index procedure.
  16. Patient has extensive peripheral vessel disease that precludes safe introducer sheath insertion.
  17. Patient has received brachytherapy in any epicardial vessel (including side branches).
  18. Pregnant or nursing subjects and those who plan pregnancy ≤ 2 years following index procedure. (Note: Female subjects of child-bearing potential must have a negative pregnancy test ≤ 28 days prior to the index procedure and agree to use contraception for 2 years.)
  19. Patient has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin, etc.) that per physician judgment that may cause non-compliance with the protocol or confound the data interpretation or is associated with a limited life expectancy (i.e., ≤ 1 year).
  20. Subject belongs to a vulnerable population (per investigator's judgment, e.g., subordinate hospital staff, mentally deficient, or unable to read or write).

Angiographic Exclusion

  1. Target lesion meets any of the following criteria:

    1. Aorto-ostial location (within ≤ 3 mm of aorta junction).
    2. Left Main location.
    3. Located ≤ 3 mm of the origin of the left anterior descending (LAD) or left coronary circumflex (LCX).
    4. Located within an arterial or saphenous vein graft or distal to a diseased (defined as vessel irregularity per angiogram and > 20% stenosed lesion, by visual estimation) arterial or saphenous vein graft.
    5. Lesion involving a bifurcation > 2 mm in diameter and ostial lesion > 40% stenosed by visual estimation or side branch requiring predilatation.
    6. Total occlusion (TIMI flow 0) prior to wire crossing.
    7. Excessive tortuosity (≥ two 45° angles), or extreme angulation (≥ 90°) proximal to or within the target lesion.
    8. Restenotic from previous intervention.
    9. Moderate to severe superficial calcification (defined as calcium arch > 120°) proximal to or within the target lesion.
  2. Target lesion involves myocardial bridge.
  3. Target vessel contains visible thrombus as indicated in the angiographic images.
  4. Another clinically significant lesion is located in the same major epicardial vessel as the target lesion (including side branches).
  5. Inadequate pre-dilation of the target lesion (residual stenosis > 40% by visual assessment).
  6. Patient has a high probability that the use of other ancillary devices such as atherectomy or cutting balloon will be required at the time of index procedure for treatment of the target vessel.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02189499

Contacts
Contact: Andrew J Ford, Jr., BS +1 650 965 3830 ext 237 aford@amaranthmedical.com

Locations
Colombia
Clinica de Marly Recruiting
Bogota, Colombia
Contact: German Gomez, MD       german.gomezmd@gmail.com   
Principal Investigator: German Gomez, MD         
Instituto del Corazon Recruiting
Bucaramanga, Colombia
Contact: Paola S Delgado, RN    + 57 3174281477      
Principal Investigator: Boris Vesga, MD         
Angiografia De Occidente S.A. Not yet recruiting
Cali, Colombia
Contact: Antonio Dager, MD       antoniodager@angiografiadeoccidente.com.co   
Contact: Jaime Fonseca, MD       jafonseca25@yahoo.com   
Principal Investigator: Antonio Dager, MD         
Centro Cardiovascular Colombiano Clinica Santa Maria (Cardiovid) Not yet recruiting
Medellin, Colombia
Principal Investigator: Carlos Alberto Eusse, MD         
EMMSA Clinica Especializada Recruiting
Medellin, Colombia
Contact: Miguel A Moncada, MD    + 57 4 4488980 ext 1339    m_moncada@yahoo.com   
Contact: Juan C Ortiz, MD    + 57 4 4488980 ext 1339    jcortizuribe@hotmail.com   
Principal Investigator: Miguel A Moncada, MD         
Sponsors and Collaborators
Amaranth Medical Inc.
Investigators
Principal Investigator: Juan F Granada, MD Skirball Center for Cardiovascular Research, Columbia University Medical Center
  More Information

Publications:
Granada JF. The Amaranth PLLA based bioresorbable scaffold (ABRS): Experimental and early human results. TCT presentation 2013.
Granada JF. BRS with clinical data III, Amaranth: Differentiating features and clinical update. TCT presentation 2014.

Responsible Party: Amaranth Medical Inc.
ClinicalTrials.gov Identifier: NCT02189499     History of Changes
Other Study ID Numbers: TP-0170
Study First Received: July 9, 2014
Last Updated: October 16, 2014
Health Authority: Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Colombia: Ethics Committee

Keywords provided by Amaranth Medical Inc.:
Stents
Angioplasty
Coronary Vessels
Coronary Artery Disease
Angina Pectoris
Myocardial Ischemia
Myocardial Infarction
Myocardial Revascularization

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Ischemia
Myocardial Ischemia
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Heart Diseases
Pathologic Processes
Vascular Diseases

ClinicalTrials.gov processed this record on October 21, 2014